Searle Company Ltd · PSX:SEARL
Searle — The Searle Company — Investor Presentation (December 2022)
15 slides from Searle's investor presentation, December 2022
Slide 1: The Searle Company Limited Corporate briefing 2022
The Searle Company Limited Corporate briefing 2022
Slide 2: Subsidiaries of Searle
Subsidiaries of Searle • Searle is 56.32% owned by IBL Group. The Searle • Originally founded in US in 1888 by Gideon D. Searle. Company Limited • Incorporated in Pakistan as a Private Limited Company in 1965 as a subsidiary of G.D. Searle & Co., USA. Listed 74.1% 90.6% 100% 100% 100% 100% IBL Searl
Slide 3: Our Footprints
Our Footprints E X C E L L E N C E I N C O M M E R C I A L O P E R AT I O N S ND 1 No. 2 1Billion Plus Billion Rupee Club i. ii. iii. iv. Cardiovascular Pain Management Gynae Cough Suppressant - Largest Pharmaceutical Company In terms of Product Consumptions(Unit) 6 Brands - Exporter in Pakistan v.
Slide 4: Achievements
Achievements COMMITMENT TO EXCELLENCE Searle was ranked as the most outstanding company in Healthcare sector of Pakistan as per Asiamoney’s Outstanding Companies Poll, 2018 & 2021. Searle has been part of Forbes Asia’s Best Under A Billion rankings from 2017 to 2019. Searle won Asia’s Best Performin
Slide 5: Pharmaceutical Industry
Pharmaceutical Industry The pharmaceutical sector recorded revenue of PKR 678bn (USD 3.5 bn) in last 12 months with YoY growth of 15.29% (against PKR 588bn in last year). Market share of Multinational & Market share of Top 100 National companies 2.80% 28.00% No. of Companies Multinational 26 Top 100
Slide 6: Our Product Portfolio
Our Product Portfolio M A R K E T I N G A U T H O R I Z AT I O N 20 651 Biotech Local Registration Registration 398 70 Global Enlistments Registration 52 6 Medical Drug Device Manufacturing Registration License
Slide 7: Our Brands
Our Brands LEADING BRANDS IN THEIR THERAPEUTIC AREA Cough • Hydryllin Muscle Relaxant • Nuberol ORS • Peditral Cardiovascular • Extor, Spiromide, Byscard Analgesic • Tramal, Rotec Gastrointestinal • Gravinate, Lomotil, Selanz Antibiotics • Negram Anaemia • Venofer Eye care • Cosopt, Trusopt
Slide 8: Our Partners
Our Partners T R U S T O F O U R A F F I L I AT O R S
Slide 9: Our Presence
Our Presence Export contributes 10% to our revenue Afghanistan Oman Myanmar Sudan Laos Senegal Nigeria Yemen Vietnam Ethiopia Cambodia Ivory Coast Uganda Sri Lanka Kenya Philippines Ghana Cameroon Rwanda Tanzania Maldives Mauritius Existing Market - 16 Future Market - 5
Slide 10: Industry Rankings
Industry Rankings SEARLE IS RANKED NUMBER 2ND IN TERMS OF VOLUME AND RANKEND 5TH IN TERMS OF VALUE Market Growth Market Growth CAGR 2022 – VOLUME IMS MAT SEP Share% % 2022 – VALUE IMS MAT SEP Share% % % GSK 367,871,446 10.32% 4.97 GETZ 42,833,844,495 6.32 16.13 15.87 SEARLE 231,573,000 6.49% 11.26 G
Slide 11: Our Revenue & Profits
Our Revenue & Profits 29.9 bn 1.3 bn 2000 2022 CAGR – 15.15% ‘Mn 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Revenue 1,342 1,507 1,566 1,733 2,065 2,337 2,818 2,694 2,722 3,124 4,176 4,877 5,659 6,014 7,609 9,048 11,328 13,310 16
Slide 12: Corporate Social Responsibility
Corporate Social Responsibility Our humble CSR efforts • Considering the importance of education and believing it to be a right of every citizen, Searle supports The Citizens Foundation to help them achieve the cause, empowering children to become agents of positive change. • Continuing with our phi
Slide 13: Our Collaboration
Our Collaboration • IBA Karachi- established the Rashid Abdulla Consumer Neuroscience Lab • NED University - established a research facility, Rashid Abdullah Research Centre • LUMS - Contributed to setup of MDR Laboratory • Karachi University - Research & Development Centre at ICCBS
Slide 14: Financial Information
Financial Information 2022 2021 2020 Revenue 17,737,282 16,569,596 16,567,219 SG&A % 34.45% 31.93% 29.65% Operating profit % 23.98% 24.48% 23.82% Standalone PAT % 11.79% 12.81% 14.82% EPS 6.70 7.01 7.87 Cash Dividend Nil 20.00% 25.00% Stock Dividend 25.00% 30.00% Nil 2022 2021 2020 Revenue 29,909,65
Slide 15: Thank you
Thank you
The Searle Company — Investor Presentation (December 2022) on 6ix